(A) Serum serotonin levels, (B–D) real-time PCR analysis of indicated genes in bones, (E and F) immunoblotting in femoral lysates, and (G and H) immunoprecipitation and immunoblotting in femoral lysates of WT, Lrp5–/–, and LP533401-treated Lrp5–/– mice. The gut-derived serotonin synthesis inhibitor LP533401 was administered daily by gavage at 200 mg/kg/d for 7 days (n = 4 mice/group). Mice were 2 months old. *P < 0.05 versus WT, #P < 0.05 versus LP533401-treated Lrp5–/– group.